Burden, risk factors and outcomes associated with adequately treated hypothyroidism in a population-based cohort of pregnant women from North India

PLoS One. 2023 Sep 13;18(9):e0282381. doi: 10.1371/journal.pone.0282381. eCollection 2023.

Abstract

Hypothyroidism is the commonest endocrine disorder of pregnancy, with known adverse feto-maternal outcomes. There is limited data on population-based prevalence, risk factors and outcomes associated with treatment of hypothyroidism in early pregnancy. We conducted analysis on data from an urban and peri-urban low to mid socioeconomic population-based cohort of pregnant women in North Delhi, India to ascertain the burden, risk factors and impact of treatment, on adverse pregnancy outcomes- low birth weight, prematurity, small for gestational age and stillbirth. This is an observational study embedded within the intervention group of the Women and Infants Integrated Interventions for Growth Study, an individually randomized factorial design trial. Thyroid stimulating hormone was tested in 2317 women in early (9-13 weeks) pregnancy, and thyroxin replacement started hypothyroid (TSH ≥2.5mIU/mL). Univariable and multivariable generalized linear model with binomial family and log link were performed to ascertain risk factors associated with hypothyroidism and association between hypothyroidism and adverse pregnancy outcomes. Of 2317 women, 29.2% (95% CI: 27.4 to 31.1) had hypothyroidism and were started on thyroxin replacement with close monitoring. Overweight or obesity was associated with increased risk (adjusted RR 1.29, 95% CI 1.10 to 1.51), while higher hemoglobin concentration was associated with decreased risk (adjusted RR 0.93, 95% CI 0.88 to 0.98 for each g/dL) for hypothyroidism. Hypothyroid women received appropriate treatment with no increase in adverse pregnancy outcomes. Almost a third of women from low to mid socio-economic population had hypothyroidism in early pregnancy, more so if anemic and overweight or obese. With early screening and adequate replacement, adverse pregnancy outcomes may be avoided. These findings highlight the need in early pregnancy for universal TSH screening and adequate treatment of hypothyroidism; as well as for attempts to reduce pre and peri-conception overweight, obesity and anemia. Clinical trial registration: Clinical trial registration of Women and Infants Integrated Interventions for Growth Study Clinical Trial Registry-India, #CTRI/2017/06/008908; Registered on: 23/06/2017, (http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=19339&EncHid=&userName=society%20for%20applied%20studies).

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Female
  • Humans
  • Hypothyroidism* / drug therapy
  • Hypothyroidism* / epidemiology
  • India / epidemiology
  • Infant
  • Obesity
  • Overweight / complications
  • Overweight / epidemiology
  • Pregnancy
  • Pregnant Women
  • Risk Factors
  • Thyrotropin
  • Thyroxine*

Substances

  • Thyroxine
  • Thyrotropin

Associated data

  • CTRI/CTRI/2017/06/008908

Grants and funding

The main trial was funded by the Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology, Government of India under the Grand Challenges India- All Children Thriving Initiative (GCIACT Ref No: BIRAC/GCI/0085/03/14-ACT) and the Bill & Melinda Gates Foundation, USA (Grant ID #OPP1191052). The funders has no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.